LEO Pharma Secures Canadian Reimbursement Deal for Chronic Hand…

Event summary

LEO Pharma finalized a Letter of Intent with pCPA for Anzupgo® (delgocitinib cream) for chronic hand eczema (CHE) in Canada.
Anzupgo® is the first topical treatment specifically indicated for moderate to severe CHE when corticosteroids are inadequate.
The DELTA clinical trial program demonstrated superiority over standard of care (oral alitretinoin) with 17% of participants being Canadian.
75% of nurses with CHE reported significant work impact, highlighting the condition's occupational health burden.

The big picture

LEO Pharma's deal with pCPA represents a strategic milestone in expanding access to specialized dermatology treatments within Canada's public healthcare system. The focus on chronic hand eczema, particularly among healthcare workers, underscores the growing recognition of occupational skin conditions as a critical public health issue. With positive clinical trial results and regulatory backing, Anzupgo® is positioned to become a standard treatment option, potentially reshaping the CHE therapy landscape.

What we're watching

Regulatory Approval: Whether INESSS in Quebec will align with pCPA's reimbursement decision and timeline.
Market Penetration: The pace at which Anzupgo® gains adoption among nurses and other high-risk occupational groups.
Competitive Dynamics: How LEO Pharma's first-to-market advantage in CHE treatment will be challenged by potential new entrants.